The production of intrathecal AQP4-IgG by CSF B cell clones indicates that future treatment in NMO may need to address both peripheral and CNS B cell populations for acute and prophylactic strategies [22-24]. This evidence concerns the gene AQP4 and neuromyelitis optica.